EQL Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

EQL Pharma heeft een totaal eigen vermogen van SEK221.0M en een totale schuld van SEK451.6M, wat de schuld-eigenvermogensverhouding op 204.3% brengt. De totale activa en totale passiva bedragen respectievelijk SEK808.8M en SEK587.8M. De EBIT EQL Pharma is SEK67.4M waardoor de rentedekking 5.2 is. Het heeft contanten en kortetermijnbeleggingen van SEK82.4M.

Belangrijke informatie

204.29%

Verhouding schuld/eigen vermogen

SEK 451.56m

Schuld

Rente dekkingsratio	5.2x
Contant	SEK 82.40m
Aandelen	SEK 221.03m
Totaal verplichtingen	SEK 587.79m
Totaal activa	SEK 808.82m

Recente financiële gezondheidsupdates

Recent updates

EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality

May 16

Pipeline Launches And Global Expansion Will Drive Future Success

May 11 Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.

Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly

Mar 12

EQL Pharma aiming for 19% Revenue Growth in 5 Years

Feb 22Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare. 

The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested

Jan 27

EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce

Dec 14

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK400.3M ) EQL } overtreffen de korte termijn passiva ( SEK220.6M ).

Langlopende schulden: De kortetermijnactiva EQL ( SEK400.3M ) overtreffen de langetermijnschulden ( SEK367.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 167% ) EQL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van EQL is de afgelopen 5 jaar gestegen van 33.2% naar 204.3%.

Schuldendekking: De operationele kasstroom van EQL is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: De rentebetalingen op de schuld van EQL worden goed gedekt door EBIT ( 5.2 x dekking).

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/16 21:32
Aandelenkoers aan het einde van de dag	2025/05/16 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

EQL Pharma AB (publ) wordt gevolgd door 1 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Erik Hultgård	Carnegie Commissioned Research

EQL Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Recent updates

EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality

Price target increased by 13% to kr87.50

Pipeline Launches And Global Expansion Will Drive Future Success

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2025/26

EQL Pharma AB (publ) to Report Q2, 2026 Results on Nov 05, 2025

Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly

EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2024/25 - 2028/29

EQL Pharma aiming for 19% Revenue Growth in 5 Years

Third quarter 2025 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 11%

EQL Pharma AB (publ) to Report Q4, 2025 Results on May 08, 2025

The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested

Investor sentiment improves as stock rises 15%

EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce

Consensus revenue estimates fall by 15%

Investor sentiment improves as stock rises 16%

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

First quarter 2025 earnings: Revenues exceed analyst expectations

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Investor sentiment improves as stock rises 16%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released

Insufficient new directors

Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)

EQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024

New major risk - Earnings quality

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Founder & Chairman recently sold kr11m worth of stock

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)

First quarter 2023 earnings released

EQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

EQL Pharma AB (Publ) Announces Approval of Mellozzan (Melatonin)

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Third quarter 2021 earnings released

EQL Pharma AB (Publ) Convenes Nomination Committee

EQL Pharma Announces Approval of Glucosparc (Metformin)

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

New 90-day high: kr40.00

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation